title: Antiphospholipid syndrome.
abstract: Antiphospholipid syndrome (APS) is defined as the presence of venous or arterial thromboses, and/or recurrent miscarriage, with evidence of antiphospholipid antibodies (aPL). Central to the disease, is the development of the antibodies to phospholipid molecules themselves, or to their binding proteins. The production of these antibodies may depend upon the unusual exposure of cytoplasmic molecules seen during the process of apoptosis. The exact pathogenesis of antiphospholipid syndrome remains unclear, but various putative models exist. These include the up-regulation of endothelial cell adhesion molecules, membrane disruption during lipid peroxidation, a dysfunction of endogenous anticoagulants, or abnormal platelet aggregation. The mainstay of treatment is with aspirin or warfarin, and more research is required to discover novel, and safer, therapies.
authors.affiliation: Centre for Rheumatology, University College London Hospitals, 40-50 Tottenham Street, London W1T 4NJ, UK. jessicamanson@doctors.org.uk
authors.forename: J J
authors.initials: JJ
authors.lastname: Manson
authors.forename: D A
authors.initials: DA
authors.lastname: Isenberg
mesh_terms: D000818:Animals; D017304:Annexin A5 / Q000276:immunology; D017152:Antibodies, Antiphospholipid / Q000276:immunology; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000188:drug therapy / Q000276:immunology*; D017209:Apoptosis / Q000276:immunology; D002448:Cell Adhesion / Q000276:immunology; D004730:Endothelium, Vascular / Q000276:immunology; D006801:Humans; D015854:Up-Regulation; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D017304:Annexin A5; D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D014859:Warfarin